Nature finds a way: The COINS Act won’t stop China biotech innovation. A Perspective by BioCentury's @Jeff_Cranmer buff.ly/WpXyeqq
In BioCentury's Finance Report: Flagship's new UK origination lab, VCs back VitriVax's Lyme disease program; rounds for Isomorphic, Marrow and Seawolf; Sellas' follow-on; and more buff.ly/D6zLaKf
Private European biopharmas make bigger acquisitions in 2026: a BioCentury Data Byte buff.ly/rCIo28E
#BCTW special podcast from London Life Sciences Week: UK regulatory innovation, China dealmaking, COINS Act and whether AI drug discovery improvements justify tech-style valuations #LLSW buff.ly/eGv33FE
Neutrophil extracellular traps can protect against infection or drive tissue damage. Five studies in BioCentury’s Innovation Radar explore ways to suppress harmful NET activity — and the risks of compromising antimicrobial defense. buff.ly/mlBzQtp
In BioCentury's latest Management Tracks: Teva's R&D leader set to depart; 858's new CEO; and more buff.ly/g6vJumm
2
636
Medicare buy-ins for older adults and guaranteed coverage for children could bring the U.S. closer to universal coverage. In a Guest Commentary, former Gore policy adviser David Beier makes the case for incremental reform over a single-payer overhaul. buff.ly/fw6OKBE
481
Seawolf Therapeutics emerged from stealth with $100M to develop DNA-LNP therapies designed to combine the durability of viral gene therapies with the repeat dosing possible with RNA-LNPs. An Emerging Company Profile by BioCentury's @DanielleGolovin buff.ly/lhIxAha
ai3Bio: Resetting the immune system with in vivo T cell depletion. Merging complementary LNP-mRNA and mAb-based approaches targeting Th17 cells for autoimmune diseases, backed by a $48M series A buff.ly/P9A7cWu
Isomorphic raises $5B in the largest biotech venture round yet. AI drug design company’s series C round comes just six months after a $2.1B round, and before a program has entered the clinic. buff.ly/Tw7bj66
Biopharmas should invest in tools to close biological AI’s data gaps — a Perspective by BioCentury's Lindsay Martin. Shared initiatives can set the foundation, but biopharmas should invest in measurements that address gaps relevant to their portfolios buff.ly/Rc9YTRM
On the latest #BioCenturyThisWeek podcast: J&J’s $2B NewCo buy, neoantigen vaccines, Overton odds $JNJ $MRK $MRNA buff.ly/DBKJyq3
6
709
FDA held Summit to its survival bar for ivonescimab in EGFR-mutant lung cancer. The pivotal trial met its PFS endpoint but missed on overall survival. Longer follow-up showed a similar survival trend favoring ivonescimab in Western and Asian patients. buff.ly/264hJ3j
In BioCentury's Deals Report: Lilly acquires stealthy oncology play Calytrix; plus J&J/Ollin, Vor/RemeGen, BioNTech/Scholar Rock, and more buff.ly/IisknQH
6
690
J&J is buying Ollin Bio, a privately held developer of a treatment for ophthalmic disorders that could compete with Roche's Vabysmo, for $2.2B up front buff.ly/6H8FIY7
1
7
613
Sofinnova Partners goes bigger with €725M Crossover II fund to support European companies for longer buff.ly/tAvCVIu
1
544
BIO’s plan for ‘securing America’s biotech century’: Trade group trying to use China as a fulcrum to advance policies to enhance U.S. competitiveness buff.ly/3S8Fwes
1
879
China’s innovation moment sees a rise in first in class: BioCentury's Simone Fishburn & Lindsay Martin's scene setter analysis for BioCentury-BayHelix China Healthcare Summit 2026 buff.ly/3Mmv7E2
2
733
EMA’s CHMP backs new medicines from Hansoh, Innovent, AstraZeneca. Two out of three new drugs recommended at Committee’s November meeting are from Chinese originators. buff.ly/Ad04wjr
1
4
774
In BioCentury's Finance Report: Windward rises 68% after pricing IPO; Rezera's listing stalls; PepGen's offering follows DM1 data; venture rounds for Neurosterix, Delix; and more buff.ly/iQq1lXy
2
720
